|Videos|July 18, 2014
PD-1 Combinations Explored in RCC
Advertisement
Episodes in this series
For High-Definition, Click
Several clinical studies will continue to investigation PD-1 inhibition in renal cell carcinoma, explains Brian I. Rini, MD. A large phase I study showed modest activity with nivolumab as a single-agent, with questions regarding a maximum tolerated dose still lingering.
The next wave of research will focus on combination strategies, specifically looking at nivolumab with a TKI, such as sunitinib or pazopanib. The most intriguing combination involves nivolumab and ipilimumab. This approach has shown promising activity for patients with melanoma, Rini notes.
View the video, to hear the discussion.
Advertisement
Related to this article
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.
Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
Niraparib/Dostarlimab Plus CRT Displays Efficacy but Has Toxicity Concerns in Locally Advanced HNSCC
Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
5